Compare NetEase Inc (NTES) vs 10X Genomics Inc (TXG) Price & Performance

NetEase (NTES) trades at $129.57, down 1.31% over the past day, with a bullish technical outlook supported by moving averages. The company reported strong Q1 2026 earnings of $2.53 EPS, beating expectations, and maintains robust profitability with a 29.84% net income margin. Recent news highlights international expansion and a Zacks Strong Buy upgrade, while the stock offers a dividend with the next payment scheduled for June 18, 2026.

The outlook for NTES is positive, driven by earnings growth, cash flow strength, and analyst optimism, with a 34.66% upside to price targets. Key risks include China market volatility and competitive pressures in gaming. The stock presents a value opportunity with a P/E of 17.26, but investors should monitor geopolitical and regulatory developments.

TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.

The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.